Drug intelligence / Profile preview

RDX013

Development stage: Phase 2
Lead developer: Ardelyx
Modality: Small Molecules
Administration: Oral

Overview

RDX013 is an orally available small molecule drug developed by Ardelyx for the treatment of hyperkalemia, a condition characterized by elevated serum potassium levels. It acts as a potassium secretagogue and functions as a potassium channel modulator to promote the excretion of excess potassium. The drug has been evaluated in Phase 2 clinical trials for patients with chronic kidney disease who have elevated serum potassium. As of the latest updates, development appears to be suspended or pending further advancement[1][2][3][5][7].

Targets

KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)

Beyond the preview

Go deeper on RDX013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDX013.

Explore the full profile